Topical toremifene: a new approach for cutaneous melanoma?

Juhani Maenpaa, Thomas Dooley, Gregory Wurz, John VandeBerg, Edward Robinson, Vernon Emshoff, Pirkko Sipila, Valerie Wiebe, Calvin Day, Michael DeGregorio

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The distribution of topically applied toremifene (0.5-1 mg/day for 5 days) in the ultraviolet B (UVB)-induced Monodelphis domestica opossum melanoma model was examined. The mean concentration of toremifene measured in the skin was 1200 nmol/g, or >500 times that detected in any other tissues (blood, brain, liver, testicles, heart, uterus, eyes). In plasma, toremifene could be detected in only one animal of six (0.04 nmol/ml). Intraperitoneal administration of 0.5 mg toremifene daily for 5 days in three female animals resulted in a mean uterus concentration of 22.9 nmol/g, or 400-fold that achieved by topical administration of 0.5 mg/day in three other female Monodelphis (0.05 nmol/g). The cytostatic effect of toremifene was studied in three human melanoma cell lines and three experimental cell lines derived from UVB-induced melanocytic nevi in M. domestica. Toremifene had a cytostatic effect on all cell lines (50% growth-inhibitory concentrations, 5.8-9.6 μM). Topical toremifene administration yields high local concentration with minimal systemic distribution. In addition, toremifene has a cytostatic effect at achievable concentrations in a variety of melanomatous cell lines.

Original languageEnglish (US)
Pages (from-to)392-395
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume32
Issue number5
DOIs
StatePublished - Sep 1993
Externally publishedYes

Fingerprint

Toremifene
Melanoma
Skin
Monodelphis
Cytostatic Agents
Cells
Topical Administration
Cell Line
Uterus
Animals
Opossums
Pigmented Nevus
Liver
Inhibitory Concentration 50
Testis
Brain
Blood
Tissue
Plasmas

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Maenpaa, J., Dooley, T., Wurz, G., VandeBerg, J., Robinson, E., Emshoff, V., ... DeGregorio, M. (1993). Topical toremifene: a new approach for cutaneous melanoma? Cancer Chemotherapy and Pharmacology, 32(5), 392-395. https://doi.org/10.1007/BF00735925

Topical toremifene : a new approach for cutaneous melanoma? / Maenpaa, Juhani; Dooley, Thomas; Wurz, Gregory; VandeBerg, John; Robinson, Edward; Emshoff, Vernon; Sipila, Pirkko; Wiebe, Valerie; Day, Calvin; DeGregorio, Michael.

In: Cancer Chemotherapy and Pharmacology, Vol. 32, No. 5, 09.1993, p. 392-395.

Research output: Contribution to journalArticle

Maenpaa, J, Dooley, T, Wurz, G, VandeBerg, J, Robinson, E, Emshoff, V, Sipila, P, Wiebe, V, Day, C & DeGregorio, M 1993, 'Topical toremifene: a new approach for cutaneous melanoma?', Cancer Chemotherapy and Pharmacology, vol. 32, no. 5, pp. 392-395. https://doi.org/10.1007/BF00735925
Maenpaa J, Dooley T, Wurz G, VandeBerg J, Robinson E, Emshoff V et al. Topical toremifene: a new approach for cutaneous melanoma? Cancer Chemotherapy and Pharmacology. 1993 Sep;32(5):392-395. https://doi.org/10.1007/BF00735925
Maenpaa, Juhani ; Dooley, Thomas ; Wurz, Gregory ; VandeBerg, John ; Robinson, Edward ; Emshoff, Vernon ; Sipila, Pirkko ; Wiebe, Valerie ; Day, Calvin ; DeGregorio, Michael. / Topical toremifene : a new approach for cutaneous melanoma?. In: Cancer Chemotherapy and Pharmacology. 1993 ; Vol. 32, No. 5. pp. 392-395.
@article{92f5fe18667f4bd0853d604fb18cd642,
title = "Topical toremifene: a new approach for cutaneous melanoma?",
abstract = "The distribution of topically applied toremifene (0.5-1 mg/day for 5 days) in the ultraviolet B (UVB)-induced Monodelphis domestica opossum melanoma model was examined. The mean concentration of toremifene measured in the skin was 1200 nmol/g, or >500 times that detected in any other tissues (blood, brain, liver, testicles, heart, uterus, eyes). In plasma, toremifene could be detected in only one animal of six (0.04 nmol/ml). Intraperitoneal administration of 0.5 mg toremifene daily for 5 days in three female animals resulted in a mean uterus concentration of 22.9 nmol/g, or 400-fold that achieved by topical administration of 0.5 mg/day in three other female Monodelphis (0.05 nmol/g). The cytostatic effect of toremifene was studied in three human melanoma cell lines and three experimental cell lines derived from UVB-induced melanocytic nevi in M. domestica. Toremifene had a cytostatic effect on all cell lines (50{\%} growth-inhibitory concentrations, 5.8-9.6 μM). Topical toremifene administration yields high local concentration with minimal systemic distribution. In addition, toremifene has a cytostatic effect at achievable concentrations in a variety of melanomatous cell lines.",
author = "Juhani Maenpaa and Thomas Dooley and Gregory Wurz and John VandeBerg and Edward Robinson and Vernon Emshoff and Pirkko Sipila and Valerie Wiebe and Calvin Day and Michael DeGregorio",
year = "1993",
month = "9",
doi = "10.1007/BF00735925",
language = "English (US)",
volume = "32",
pages = "392--395",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Topical toremifene

T2 - a new approach for cutaneous melanoma?

AU - Maenpaa, Juhani

AU - Dooley, Thomas

AU - Wurz, Gregory

AU - VandeBerg, John

AU - Robinson, Edward

AU - Emshoff, Vernon

AU - Sipila, Pirkko

AU - Wiebe, Valerie

AU - Day, Calvin

AU - DeGregorio, Michael

PY - 1993/9

Y1 - 1993/9

N2 - The distribution of topically applied toremifene (0.5-1 mg/day for 5 days) in the ultraviolet B (UVB)-induced Monodelphis domestica opossum melanoma model was examined. The mean concentration of toremifene measured in the skin was 1200 nmol/g, or >500 times that detected in any other tissues (blood, brain, liver, testicles, heart, uterus, eyes). In plasma, toremifene could be detected in only one animal of six (0.04 nmol/ml). Intraperitoneal administration of 0.5 mg toremifene daily for 5 days in three female animals resulted in a mean uterus concentration of 22.9 nmol/g, or 400-fold that achieved by topical administration of 0.5 mg/day in three other female Monodelphis (0.05 nmol/g). The cytostatic effect of toremifene was studied in three human melanoma cell lines and three experimental cell lines derived from UVB-induced melanocytic nevi in M. domestica. Toremifene had a cytostatic effect on all cell lines (50% growth-inhibitory concentrations, 5.8-9.6 μM). Topical toremifene administration yields high local concentration with minimal systemic distribution. In addition, toremifene has a cytostatic effect at achievable concentrations in a variety of melanomatous cell lines.

AB - The distribution of topically applied toremifene (0.5-1 mg/day for 5 days) in the ultraviolet B (UVB)-induced Monodelphis domestica opossum melanoma model was examined. The mean concentration of toremifene measured in the skin was 1200 nmol/g, or >500 times that detected in any other tissues (blood, brain, liver, testicles, heart, uterus, eyes). In plasma, toremifene could be detected in only one animal of six (0.04 nmol/ml). Intraperitoneal administration of 0.5 mg toremifene daily for 5 days in three female animals resulted in a mean uterus concentration of 22.9 nmol/g, or 400-fold that achieved by topical administration of 0.5 mg/day in three other female Monodelphis (0.05 nmol/g). The cytostatic effect of toremifene was studied in three human melanoma cell lines and three experimental cell lines derived from UVB-induced melanocytic nevi in M. domestica. Toremifene had a cytostatic effect on all cell lines (50% growth-inhibitory concentrations, 5.8-9.6 μM). Topical toremifene administration yields high local concentration with minimal systemic distribution. In addition, toremifene has a cytostatic effect at achievable concentrations in a variety of melanomatous cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0027321521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027321521&partnerID=8YFLogxK

U2 - 10.1007/BF00735925

DO - 10.1007/BF00735925

M3 - Article

C2 - 8339391

AN - SCOPUS:0027321521

VL - 32

SP - 392

EP - 395

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -